Clinical Trial Update: A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab alone or with bevacizumab vs sunitinib in untreated advanced renal cell carcinoma; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Sunitinib (sunitinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-12-21